Cesium carbonate → HCID 66562878, 화합물

HRID 527874

반응식

HRID 527874 반응식
[I:1][C:2]1[C:3]([S:11][C:12]2[NH:13][C:14]3[C:19]([N:20]=2)=[C:18]([NH2:21])[N:17]=[CH:16][N:15]=3)=[CH:4][C:5]2[O:9][CH2:8][O:7][C:6]=2[CH:10]=1.C([O-])([O-])=O.[Cs+].[Cs+].Br[CH2:29][CH2:30][CH2:31][CH2:32][CH2:33][C:34]([NH2:36])=[O:35]>CN(C=O)C>[NH2:21][C:18]1[N:17]=[CH:16][N:15]=[C:14]2[C:19]=1[N:20]=[C:12]([S:11][C:3]1[C:2]([I:1])=[CH:10][C:6]3[O:7][CH2:8][O:9][C:5]=3[CH:4]=1)[N:13]2[CH2:29][CH2:30][CH2:31][CH2:32][CH2:33][C:34]([NH2:36])=[O:35]

참가 물질

5

반응물 3

HCID 10796Cesium carbonateHCID 3219746-BromohexanamideHCID 178508697HCID 178508697, 화합물

생성물 1

HCID 66562878HCID 66562878, 화합물

시약·촉매·용매 1

HCID 6228Dimethylformamide용매

실험 절차

50 mg (0.121 mmol) of 8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-6-amine (S13-1) was dissolved in DMF (2 mL). 47 mg (0.145 mmol) of Cs2CO3 and 117.4 mg (0.605 mmol) of 6-bromohexanamide (S13-2) were added and the mixture was stirred at rt for 2 h. Solvent was removed under reduced pressure and the resulting residue was purified by preparatory TLC (CH2Cl2:MeOH—NH3 (7N), 10:1) to give 12.7 mg (20%) of DZ5-49-N9. 1H NMR (500 MHz, CDCl3/MeOH-d4): δ 8.13 (s, 1H), 7.31 (s, 1H), 6.97 (s, 1H), 5.98 (s, 2H), 4.13 (t, J=7.6 Hz, 2H), 2.14 (t, J=7.6 Hz, 2H), 1.71-1.80 (m, 2H), 1.55-1.65 (m, 2H), 1.28-1.39 (m, 2H); HRMS (ESI) m/z [M+H]+ calcd. for C18H20IN6O3S, 527.0362. found 527.0364.

후처리

  1. customSolvent was removed under reduced pressure
  2. customthe resulting residue was purified by preparatory TLC (CH2Cl2:MeOH—NH3 (7N), 10:1)
  3. customto give 12.7 mg (20%) of DZ5-49-N9

출처 및 근거

ORD 기록
ord-d0d2841fa97e49e4983e0fc99e7b1a2c
출처 데이터셋
uspto-grants-2016_05
특허 번호
US09346808B2

연결된 노트

불러오는 중…